Following the establishment of intracranial CT-2A tumours (Supplementary Fig. 4), we tested whether systemic administration by oral gavage of the SMC, LCL161, could cause the transient degradation of its primary targets proteins, cIAP1 and cIAP2, within intracranial murine tumours. Here, BIRC3 is linked to neoplasm.